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Abstract 
A new algorithm and web server, mutation3D (http://mutation3d.org), proposes driver genes in 
cancer by identifying clusters of amino acid substitutions within tertiary protein structures. We 
demonstrate the feasibility of using a 3D clustering approach to implicate proteins in cancer 
based on explorations of single proteins using the mutation3D web interface. On a large scale, 
we show that clustering with mutation3D is able to separate functional from non-functional 
mutations by analyzing a combination of 8,869 known inherited disease mutations and 2,004 
SNPs overlaid together upon the same sets of crystal structures and homology models. Further, 
we present a systematic analysis of whole-genome and whole-exome cancer datasets to 
demonstrate that mutation3D identifies many known cancer genes as well as previously 
underexplored target genes. The mutation3D web interface allows users to analyze their own 
mutation data in a variety of popular formats and provides seamless access to explore mutation 
clusters derived from over 975,000 somatic mutations reported by 6,811 cancer sequencing 
studies. The mutation3D web interface is freely available with all major browsers supported. 
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Introduction 
A hallmark of the genomic era has been the application of whole-genome and whole-exome 
sequencing to the study of genetic disease, especially cancer. This effort has led to the 
development of new statistical methods (Hodis, et al., 2012; Lawrence, et al., 2013; Sjöblom, et 
al., 2006), which have identified many potential genomic targets of interest by combing the 
deluge of data produced by large cohort studies. While these methods have been largely 
successful in identifying genes with previously unknown roles in tumorigenesis, we have yet to 
fully realize the promised boon to development of therapies—although the list of potential 
disease-causing and driver mutations has grown, the list of approved therapeutics has remained 
static (Das, et al., 2014). 
Although the underlying causes of this time lag are complex, they can at least be partially 
attributed to the level of resolution of current methods, which typically identify potentially 
functional genes based on mutation frequencies at the level of whole genes (Cancer Genome 
Atlas, 2012; Lawrence, et al., 2014; Vucic, et al., 2012; Wood, et al., 2007). However, many 
genes carry out a diverse set of functions (pleiotropy), the derangement of any one of which may 
be sufficient to cause cancer. Further, disruption of different functions of the same gene often 
lead to clinically distinct types of cancer (Hanahan and Weinberg, 2011; Muller and Vousden, 
2013). Finally, even when a specific gene has been identified as being potentially involved in 
tumorigenesis, researchers may have little idea as to which of its functions has been disrupted. 
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All of these challenges facing current methodologies make it difficult to develop targeted 
therapeutic strategies. 
Here we present mutation3D, an algorithm and web server (http://mutation3d.org) designed 
to identify somatic cancer-causing genes by leveraging the structure-function relationships 
inherent in their protein products. In tumorigenesis, mutations are selected that confer a 
competitive advantage to pre-cancerous cells. Since many mechanisms of tumorigenesis involve 
alterations to protein function, and protein function is determined by protein structure, 
tumorigenically selected driver mutations may localize to positions that will affect protein 
structures. Therefore, mutations causing the same cancer type in a cohort of patients may form 
clusters (or hotspots) in regions of protein structures wherein alterations confer a competitive 
advantage to tumor cells by disrupting specific protein functions. For instance, mutations 
localized at interaction interfaces may disrupt protein complexes or transient interactions, and 
mutations localized in the hydrophobic core may destabilize the protein entirely (Kucukkal, et 
al., 2015; Nishi, et al., 2013; Petukh, et al., 2015).  
Recent studies have begun to leverage structure-function relationships in proteins to predict 
cancer gene targets by searching for nonrandom distributions of mutations in protein crystal 
structures (Kamburov, et al., 2015) and enrichment across protein domains (Miller, et al., 2015). 
We present the first tool to identify and visualize individual clusters within protein structures. 
Furthermore, we also provide an option to search for clusters in homology models, expanding 
our coverage of the human proteome more than three-fold (Supp. Note S1). Through an intuitive, 
freely available web interface, researchers can use mutation3D to inspect clusters of amino acid 
substitutions in an interactive molecular viewer to determine whether to follow up with the target 
based on its structural features. Furthermore, mutation3D can analyze data from whole-genome 
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sequencing (WGS; abbrev. also including whole-exome) studies to perform cluster analysis of 
variants at the level of the structural proteome. 
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Methods 
mutation3D clustering algorithm 
The algorithm underlying the mutation3D web interface is complete-linkage (CL) clustering 
(Sørensen, 1948), a hierarchical clustering method in which clusters first comprise single 
elements and are then merged with nearest neighboring clusters or unassigned elements until a 
single cluster comprises all elements. Notably, the clusters found by complete-linkage clustering, 
as opposed to single-linkage clustering (Sneath, 1957), are assured to have a diameter less than 
or equal to a specified linkage distance, which results in tight well-defined clusters. Because of 
this property, this method can also be referred to as furthest-neighbor clustering, since the 
dissimilarity of elements within a cluster is determined by the distance between the two elements 
furthest from each other in n-dimensional space. 
In our implementation of this classic machine learning algorithm, we cluster the three-
dimensional locations of the α-carbons of those amino acids whose codons contain missense 
mutations. The coordinates of all atoms within proteins were derived from both PDB structures 
and structural models (Pieper, et al., 2011) based on PDB entries covering proteins either in part 
or in full. For any given protein, many overlapping models may be available from either or both 
sources. mutation3D will invariably use entries from the PDB when they are available, as these 
experimentally determined crystal structures are considered to be a ‘gold standard’ in structural 
biology. To increase structural coverage of the proteome, the user may also select a subset of 
homology-based models to include, based upon several quality metrics available via the 
Advanced Query page (Supp. Note S2). Once a set of PDB structures and structural models has 
been established for a single protein, mutation3D attempts to cluster amino acid substitutions on 
all models separately, and reports any model or experimentally determined structure in which a 
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cluster has been found. In our analyses, we consider it sufficient to implicate a protein in cancer 
if any of its models are found to contain a cluster. 
Some whole proteins or regions of proteins may not have been crystallized or modeled to-
date. Owing to the lack of structural coordinates in these regions, we would be unable to identify 
clusters of mutations. There are some cases in which a single genomic mutation may give rise to 
defects to distinct proteins, in which case mutation3D will attempt to find clusters across all 
proteins and models for which this mutation has an effect on protein products. 
Users may elect to set the CL-distance, or the maximum allowable distance between α-
carbons in a cluster of substituted amino acids. We refer to this as the maximum cluster diameter 
as this is equivalent to the maximum allowable diameter in Angstroms of a sphere encapsulating 
all α-carbons in a cluster. With regard to the complete linkage clustering algorithm, the CL-
distance is the maximal dissimilarity between elements, after which no new merging of elements 
and groups of elements occurs. In mutation3D, we call this parameter the Maximum Clustering 
Diameter, which is measured in Angstroms, and represents the maximum distance between 
amino acid substitutions after which no further merging of single mutations with clusters occurs 
and clusters are assigned based on current hierarchical groupings of mutations. For more 
information on all algorithm parameters and their default values, see Supp. Notes S2 and S3. 
 
Statistical significance of clusters 
In order to calculate the statistical significance of clusters found by complete-linkage clustering, 
mutation3D performs an iterative bootstrapping method to calculate a background distribution of 
cluster sizes arising from a random placement of an equivalent number of substitutions in a given 
protein structure. By default, mutation3D will randomly rearrange all amino acid substitutions 
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15,000 times in a given structure and calculate the minimum CL-distance at which a cluster of 
size n (where n is all cluster sizes found in the original data) is observed in the randomized data. 
For each cluster in the original data, P-values are computed empirically as the percentile rank of 
its CL-distance among all CL-distances for randomized clusters containing the same number of 
amino acid substitutions. The clustering algorithm/statistical significance calculator is 
implemented in C++ and is available for download as a command-line tool. 
There is precedent, even within cancer gene detection, for the use of iterative bootstrapping 
methods when the background distributions are unclear or complicated (Hodis, et al., 2012; 
Lawrence, et al., 2014). Here we use bootstrapping to account for vastly different configurations 
of the protein backbone in different protein structures. 
 
Compiling a protein structure and model set 
In order to build a repository of protein structures and models, we curated experimentally-
determined crystal structures from the PDB and homology models from ModBase by searching 
for canonical isoforms of Swiss-Prot structures or chains in both. Since many PDB structures 
provide too little coverage of their target proteins to be useful for clustering, we retained only 
those structures that cover at least 250 amino acids or 40% of their target protein. We only 
retained ModBase models that have an MPQS score ≥ 0.5, and maintain a default cutoff of 
MPQS ≥ 1.1 in the mutation3D interface and in our analyses. All structures and models were 
compared against each other to remove redundancies (i.e. a ModBase model that is of higher 
quality than, and whose range of amino acids is entirely contained within, a second ModBase 
model derived from the same PDB structure was considered not to add any novel structural 
information to our repository). Furthermore, the amino acid indices of all models and structures 
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were realigned using SIFTS (Velankar, et al., 2013) to match the amino acid indices of the 
Swiss-Prot protein they represent. 
 
mutation3D web interface 
To build the mutation3D web interface, we leveraged the power and flexibility of several well 
known JavaScript packages, such as JQuery and Bootstrap, in addition to a package designed to 
draw static two-dimensional figures (KineticJS). The cornerstone of our display system is an 
entirely JavaScript-based molecular viewer, GLmol, which allows users to view interactive 3D 
protein structures natively in modern web browsers supporting the new WebGL standard, 
without downloading any additional software. We have made modifications to these software 
packages to allow triggering of events by the user, such as highlighting mutations and mutation 
clusters simultaneously in the 3D and 2D representations of proteins. 
To speed up web accession for both single and batch queries, mutation3D runs on a multi-
core web server and the calculation of clusters is distributed among available computing cores 
using multithreaded CGI programs. 
 
Compiling mutations and variants affecting aromatase  
We compiled a list of all inherited missense mutations from the Human Gene Mutation Database 
(Stenson, et al., 2014) (HGMD) that (i) occurred within the exons of the CYP19A1 gene [MIM# 
107910] encoding the protein aromatase and (ii) have been shown in the primary literature to 
cause aromatase deficiency [MIM# 613546] (Supp. Table S1). We also compiled a set of all 
missense SNPs with total minor allele frequency (MAF) ≥ 1% (combined African and European 
ancestry) from the Exome Sequencing Project (Fu, et al., 2013) (ESP) that give rise to amino 
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acid substitutions in aromatase (Supp. Table S2). Please note that nucleotides are indexed in 
coding sequences, using the A of the ATG translation initiation start site as nucleotide 1. Visual 
inspection was performed by highlighting Cα positions in aromatase (PDB: 3S79) using PyMol 
(Schrodinger, 2010). 
 
Segregating disease mutations from SNPs  
For each Swiss-Prot protein from UniProt, a set of pathogenic inherited mutations from HGMD 
(Stenson, et al., 2014) was assembled for the catalogued disease with the greatest number of 
associated mutations in that protein. Proteins with fewer than three pathogenic mutations (two of 
which were required to occur at unique amino acid positions) associated with any one disease 
were not considered, as this is the minimum requirement for identifying a cluster with default 
mutation3D parameters (Supp. Notes S2 and S3). Separately, we assembled non-synonymous 
SNPs (nsSNPs) with MAF ≥ 1% from the ESP 6500 set, only retaining proteins if there were at 
least three SNPs in the protein, two of which caused amino acid substitutions at unique amino 
acid positions. We intersected these two sets and only retained proteins that occurred in both sets 
as meeting the individual criteria of three mutations from each set, two of which must have been 
at unique amino acid positions, for a total of 6 or more variants per protein. In total, we retained 
8,869 inherited disease-associated mutations from HGMD and 2,004 nsSNPs from ESP 6500 in 
336 proteins. 
We used mutation3D to identify clusters in the resulting proteins, employing a fairly strict 
definition of a cluster whereby a cluster was identified if three or more substitutions were found 
within the complete linkage clustering distance of 15 Å, with at least two substitutions occurring 
at unique amino acid locations. 3D model sets were derived from PDB structures and ModBase 
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models indicated to be of high quality by an MPQS ≥ 1.1 (full details on default parameters for 
mutation3D are available in Supp. Notes S2 and S3). We report the average per-protein 
clustering rates across all proteins for which models from the correct set were available. P-values 
were calculated using a U test. 
 
Measuring the overlap between mutation3D-implicated genes and the Cancer Gene Census 
To assess how efficiently mutation3D is able to capture validated cancer genes, we ran 
mutation3D with default parameters (Supp. Notes S2 and S3) on all WGS screens in COSMIC 
v75 (285 studies). We varied the maximum cluster diameter from 5 Å to 25 Å and identified the 
fraction of proteins implicated (as having one or more clusters of amino acid substitutions) that 
are known cancer genes. We define known cancer genes to be the union of genes included in the 
Cancer Gene Census (Futreal, et al., 2004) and MutSig drivers list (Lawrence, et al., 2014). 
These overlaps were computed as the number of gene overlaps with the known cancer genes 
divided by the total number of genes implicated by mutation3D in each tissue category and 
overall (this is also known as the precision or positive predictive value (PPV)):  
 
PPV = TP / ( TP + FP ) 
 
where TP is the number of true positives and FP is the number of false positives predicted by 
mutation3D. It should be noted that since the our set of known cancer genes is far from 
complete, this estimation is likely to represent the lower bound of the true precision of our 
method. Furthermore, we acknowledge that even genes in the set of known cancer genes may not 
be drivers in all cancer types. However, the overlap between our results and the known cancer 
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genes is likely to correlate with the underlying precision of our method and there is no reason to 
believe that the overlap will be biased in certain cancer types. Therefore, this measurement can 
be used to estimate the lower bound of the precision of our method in comparing its performance 
across different cancer types. Calculation of sensitivity and specificity is inappropriate in this 
instance because no method could re-capitulate all known cancer genes as no data set (single 
WGS study or a group of WGS) can be assumed to harbor all mechanisms underlying 
tumorigenesis. We also computed the overlap of all genes in these 285 COSMIC studies with 
known cancer genes for each tissue category and across all tissues, to show that performing 3D 
clustering at any maximum cluster diameter increases precision over random expectation for this 
data set. P-values were calculated using a Z test to compare each fraction of identified genes by 
clustering at different diameter thresholds to the fraction of identified genes without clustering. 
 
Assessing the likelihood of mutations clustered with mutation3D to be causal 
In addition to predicting driver genes based on those found to contain clusters, mutation3D has 
the ability to predict those mutations likely to drive cancer phenotypes by their inclusion in 
clusters. Here, we used two proxies for causal driver mutations: that they should be more likely 
to be damaging and they should be more frequently observed in WGS studies. 
We determined PolyPhen-2 scores (using the HumVar-trained model for assigning 
categories) of those mutations likely to be most deleterious biochemically based on a Grantham 
score (Grantham, 1974) in the top 25%. This shows how a combined biochemical and 
evolutionary genetics approach could lead to the discovery of new driver mutations. PolyPhen-2 
scores were accessed using the Ensembl Variant Effect Predictor, assembly GRCh38.p5 
(http://www.ensembl.org/Tools/VEP) (McLaren, et al., 2010). 
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We further determined the fraction of mutations from WGS studies found in clusters that are 
observed at high frequencies (in the top 2%) throughout COSMIC WGS studies. 
 
 
Results 
Single-protein spatial mutation case studies 
The specific relationship between 3D regions of protein structure and their functions can be 
illustrated by the proximity of amino acid substitutions arising from known disease-causing and 
cancer-associated mutations in tertiary protein structures. We searched the Human Gene 
Mutation Database (Stenson, et al., 2014) (HGMD), a large-scale disease database of gene 
mutations causing human inherited disease, and the Catalogue of Somatic Mutations in Cancer 
(Forbes, et al., 2011) (COSMIC), a somatic cancer mutation database, for examples of spatially 
specific disruptions that might explain disease phenotypes. This is intended as a proof-of-
principle, showing that there is a plausible connection between the spatial arrangement of 
mutations and disruptions of function, and that this relationship can be quickly captured through 
visual inspection. 
 
Disease mutations and nsSNPs segregate in aromatase 
According to HGMD, aromatase deficiency is known to be caused by at least 9 unique missense 
mutations in the cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1) gene 
leading to amino acid substitutions at 8 positions along the aromatase protein backbone (Supp. 
Table S1). The Exome Sequencing Project (ESP) 6500 data set (Fu, et al., 2013) contains two 
common non-synonymous SNPs (nsSNPs) with MAF ≥ 1% in this gene, which we consider 
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likely to be benign given their high frequency of occurrence (Supp. Table S2). Based on the 
primary sequence alone, no clear pattern or separation can be detected between the disease 
mutations and nsSNPs (Figure 1a). However, when we inspect the locations of these two classes 
of mutation on an experimentally-determined crystal structure of aromatase (PDB: 3S79 in 
Figure 1a), it is evident that the verified disease mutations and common nsSNPs are localized in 
quite different regions of the protein, suggesting somewhat different functional consequences 
depending upon the location of a mutation within the tertiary structure of the protein.  
 
Commonly observed cancer mutations form a tight cluster in GTPase KRas 
Cancer mutations may also aggregate within clusters in protein structures, and this aggregation is 
likely to have profound implications for our ability to differentiate functional driver mutations 
from neutral passenger mutations. Consider the canonical oncogenic protein GTPase KRas: the 
tight clustering of commonly mutated amino acid substitutions in codons 12, 13 and 61 suggests 
that these mutations cause similar structural perturbations that may lead to many types of cancer 
(Figure 1b). In fact, it has long been known that substitutions in these codons confer 
tumorigenesis, and several mechanisms have been proposed (Pylayeva-Gupta, et al., 2011) 
(Supp. Note S4, Supp. Table S3). Interestingly, another amino acid substitution E49K has only 
been reported once in a single patient (Guedes, et al., 2013) and is predicted to be benign by 
PolyPhen-2 (Adzhubei, et al., 2010). The clear spatial separation of the known driver mutations 
from the putatively benign mutation indicates a highly specific correlation between protein 
structure and function in cancer. Owing to its very high mutation frequency in many different 
types of cancer, KRAS [MIM# 190070] is readily identifiable as tumorigenic by many methods; 
however, mutation3D is uniquely positioned to be able to detect similar cases of spatially 
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specific disruption in proteins currently unknown for their roles in tumorigenesis by relating 
cancer sequencing data to aberrations in the structural proteome. 
 
 
Coordinating mutations and structural data into a tool for whole-genome inference 
mutation3D identifies mutations that group together to form statistically significant clusters on 
the folded protein backbone based on atomic coordinates derived from experimentally 
determined crystal structures and homology models. Cluster significance is measured by an 
iterative bootstrapping model, in which observed mutations are randomly rearranged on a protein 
structure, and the size of the observed cluster is ranked compared to all randomly derived 
clusters to compute an empirical P-value (see Methods for details). The accompanying web 
interface provides visualization of these clusters as well as the ability to rapidly switch views 
between all available structures. Figure 2 describes the curation of structural and mutation data, 
and user accession and download procedures. 
 
Structural data underlying mutation3D 
In assembling a set of protein structures and models for use with mutation3D, we relied on the 
huge advances made in structural proteomics over the past decade. Alongside the explosion of 
genomic sequencing data, the availability of structural proteomic data, including crystal 
structures and homology models, has increased dramatically. In 2003, there were 25,864 crystal 
structures in the Protein Data Bank (Berman, 2000) (PDB), covering 6.7% of the human 
proteome. Now, with the number of entries in the PDB exceeding 100,000, we can visualize 
nearly 90% (with reasonable accuracy and coverage—see Supp. Figure S1) of the human 
proteome through a combination of experimentally-determined crystal structures and structural 
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models based on shared structural elements among homologous proteins. mutation3D curates 
both crystal structures from the PDB and high-quality homology models from ModBase (Pieper, 
et al., 2011) to populate its repository of over 135,000 protein structures (Figure 2a). This 
significant underpinning of structural proteomic data ensures that mutation3D is useful for large-
scale sequencing projects, as nearly all DNA mutations of interest within coding regions will be 
mappable to 3D locations in protein structures. 
 
Seamless access to large-scale somatic cancer mutation sets 
Perhaps the richest large-scale source of missense mutation data derives from WGS studies of 
cancer patient cohorts. According to COSMIC, in the year 2003, 187 peer-reviewed articles were 
published reporting on average a single gene with protein-altering somatic mutations in tumor-
normal sequencing studies. In 2012, 572 studies reporting an average of 144 mutated genes were 
published. With the growing ease of sequencing, the scientific community has largely embraced 
the wholesale sequencing of tumor samples, and an accompanying class of statistical methods to 
identify genes characterized by elevated mutation rates across large patient cohorts (Cancer 
Genome Atlas, 2012; Hodis, et al., 2012; Lawrence, et al., 2014; Lawrence, et al., 2013; 
Sjöblom, et al., 2006; Wood, et al., 2007). These methods have been largely successful, and have 
led to the discovery of many genes previously not known to be involved in tumorigenesis. 
However, studying cancer at the level of whole genes ignores the fact that many genes and their 
protein products perform multiple cellular functions (pleiotropy). By incorporating available 
protein structures and models into cancer gene detection, we can harness the inherent structure-
function relationship in proteins to identify more specific tumorigenic etiologies based on 
specific spatial disruptions that could become therapeutic targets. 
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The mutation3D web interface allows users to rapidly analyze pre-processed missense 
mutation data from the most recent build of COSMIC through intuitive web forms on the 
Advanced query page (http://mutation3d.org/advanced_form.shtml, click the COSMIC tab under 
Data Source). Currently, we have catalogued over 975,000 missense mutations in 6,811 primary 
cancer sequencing studies that users can search for by author, journal, PMID and size of dataset 
(Figure 2b). Additionally, users may choose to tune the default clustering parameters (Supp. 
Note S3) and protein structural model set (Supp. Note S2) based on the types of evidence needed 
to support clusters for their specific application. A list of candidates, with links to 3D views of 
the mutations overlaid onto structural models (Figure 2c), are retrieved within seconds, even for 
the largest WGS studies in COSMIC. 
 
mutation3D identifies well-validated gene candidates and plausible new targets 
We ran mutation3D on large sets of known inherited disease and cancer mutations to 
demonstrate the power of clustering to reveal shared etiologies in the structural proteome. Here, 
and in all following large-scale analyses, mutations associated with each distinct disease 
phenotype are considered separately from mutations associated with unrelated phenotypes so that 
a correspondence can be made between clusters in functionally relevant parts of protein 
structures and potential defects in molecular function that may cause one specific disease or type 
of cancer. We demonstrate the ability of mutation3D to distinguish functional from non-
functional mutations in disease and to re-discover many known cancer-causing genes as well as 
discovering several new putative targets. Parameters for all tests performed are available in 
Methods and in Supp. Table S4. 
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mutation3D distinguishes disease mutations from common variants 
To illustrate the efficacy of mutation3D in distinguishing functional from non-functional 
variants, we considered all proteins harboring at least 3 mutations associated with a single 
disease (according to HGMD) and all missense population variants (SNPs) from the ESP 6500 
data set for this same set of proteins (see Methods for details). We were able to show that the 
resulting set of 8,869 disease-causing amino acid substitutions are more likely to be clustered by 
mutation3D than are 2,004 putatively benign substitutions arising from missense SNPs when 
considering only those mutations associated with a single disease at a time mixed together with 
SNPs in the same proteins (Figure 3a-b). This trend is apparent irrespective of whether the 
protein structure set is confined to known PDB structures, homology models from ModBase, or a 
combination of the two. 
This analysis illustrates mutation3D’s ability to distinguish functional from non-functional 
variants when all functional variants share an associated phenotypic consequence. Because it is 
often difficult to determine which cancer mutations are drivers and which are passengers, 
mutation3D’s ability to distinguish functional disease mutations from non-functional SNPs 
serves as a proxy measure of its ability to separate functional driver mutations from a 
background of largely non-functional passenger mutations. 
 
mutation3D identifies both new and well-known cancer genes 
To confirm that mutation3D identifies plausible driver gene candidates in cancer (as judged by 
the existence of one or more clusters of substitutions in structures of their protein products), we 
computed statistically significant clusters from mutations in all WGS studies cataloged by 
COSMIC. First, we calculated the proportion of the identified cancer candidates that have been 
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previously proposed as cancer drivers based on a combination of the Cancer Gene Census 
database (Futreal, et al., 2004) and the MutSig driver list (Lawrence, et al., 2014). This is likely 
to be correlated with the lower bound of precision, or positive predictive value, of our method 
(see Methods). Figure 3c illustrates the calculated proportion values for all publications analyzed 
and for specific tissues within these studies, plotted over several cluster sizes. The results concur 
with our expectation that tighter mutation clusters should exhibit high precision for known 
cancer genes since substitutions in close physical proximity will be more likely than distant 
substitutions to be contained within the same interface domain or within the hydrophobic protein 
core. As expected, we also observe lower precision in the identification of genes involved in 
cancers of the skin, which are characterized by very high mutation rates (Alexandrov, et al., 
2013). By contrast, cancers of the breast are known to harbor driver mutations in a relatively 
small number of genes and contain a relatively low proportion of passenger mutations (Kan, et 
al., 2010), thereby allowing mutation3D to precisely identify known cancer genes irrespective of 
cluster size. 
To confirm that our statistical model yields plausible measures of cluster significance, we 
computed the statistical significance of clusters found in COSMIC WGS data. We find that our 
iterative bootstrapping model (See Methods) produces P-values that are highly correlated with 
the likelihood of a gene to be a known cancer genes (Figure 3d). We repeated both this and the 
study in Figure 3c using the Cancer Gene Census and MutSig cancer gene list separately to 
define a list of known cancer genes. We find the relative observed trends remain the same, 
confirming the robustness of our analyses (Supp. Figure S2). 
We also find that the somatic mutations within these clusters are predicted to be more 
deleterious by PolyPhen-2 when found in smaller, more specific clusters (Figure 3e). 
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Furthermore, mutations within clusters are observed at much higher frequencies within WGS 
studies, suggesting they are likely to be driver mutations (Figure 3f). Overall, these analyses 
suggest a tendency for functionally important mutations to form clusters in cancer patient 
cohorts, whereas less important passenger mutations are more likely to fall outside these clusters. 
We next investigated whether mutation3D preferentially reports potential oncogenes or 
tumor suppressors. We find that of genes annotated in either class based on the Cancer Gene 
Census, there is not a significant difference in the likelihood mutation3D will find clusters within 
their protein products (Supp. Note S5, Supp. Figure S3). This suggests that mutation3D is 
equally robust in its ability to detect oncogenes and tumor suppressors. 
Finally, we produced a list of the genes whose protein products most commonly exhibit 
clusters of mutations within the same set of COSMIC WGS publications. We find that 
mutation3D implicates many well-known cancer genes (TP53, KRAS, EGFR, BRAF, etc.) as well 
as some genes that are missing from the Cancer Gene Census (Figure 4a). Visual inspection of 
the most significant clusters for each of these proposed genes demonstrates the power of 3D 
clustering (Figure 4b).  A list of all genes found in at least 4 studies across COSMIC is available 
in Supp. Table S5. 
 
Discussion 
Researchers have already begun to acknowledge the added benefit of linear clustering 
approaches to the detection of driver mutations in two recently proposed methods (Lawrence, et 
al., 2014; Tamborero, et al., 2013). However, these methods do not take into account the 3D 
positions of mutations within protein products, disregarding information available due to 
structure-function relationships in proteins. Two other recent methods (Ryslik, et al., 2012; 
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Ryslik, et al., 2014) perform 1D clustering of mutations after a projection of 3D structural 
coordinates into 1D, potentially resulting in loss of information (Supp. Note S6, Supp. Figure 
S4). Clustering methods have also been used to detect signatures of positive selection (Tusche, et 
al., 2012; Wagner, 2007; Zhou, et al., 2008); however, the goals and assumptions of these 
methods and mutation3D are quite different (Supp. Note S7, Supp. Figure S5). Another recent 
method detects non-random distributions of mutations in protein crystal structures (Kamburov, et 
al., 2015). Although this method has shown in principle that 3D structural information is 
valuable for identifying target genes, it does not distinguish individual clusters and its analysis is 
limited to PDB structures.  
Compared to the standard class of methods that do not search for clusters of amino acid 
substitutions, but instead employ measures of mutation frequency at the gene level to detect 
drivers of cancer, the added value of mutation3D lies in its orthogonal use of protein structures to 
make a more direct connection between alterations of structure and disruptions of function. We 
do not intend that mutation3D should replace these methods (Hodis, et al., 2012; Lawrence, et 
al., 2013; Sjöblom, et al., 2006). Instead, mutation3D gives scientists the ability to inspect their 
data through an additional lens—to visualize and form hypotheses about functional gene and 
protein candidates proposed by any method of cancer gene detection, and to find cases in which 
directly searching for structural disruptions may provide insights not available by other means. 
Even beyond its potential to improve candidate gene identification, mutation3D is valuable 
simply in terms of its ability to display mutations on all available high-quality structures and 
models, a task that requires significant effort on any scale without mutation3D, and can be 
accomplished on massive scales with mutation3D.  
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Throughout this study, we have evaluated the ability of mutation3D to identify whether or 
not a gene is involved in cancer because this is a standard for the cancer gene detection methods 
of today. However, such a metric may underrate the true ability of mutation3D, which can 
propose specific tumorigenic etiologies based on the structural localization of mutations. Even in 
cases where mutation3D identifies the same gene as another method, analyzing and viewing the 
mutations using mutation3D may present a specific hypothesis supported by both statistical and 
structural evidence, which may be more likely to inspire follow-up studies. 
In addition to providing structural evidence for single proteins, the mutation3D web interface 
(http://mutation3d.org) allows users to rapidly search for clusters of mutations in the proteome 
(by inputting their data in a variety of popular genomic and proteomic formats), view and 
download clustering reports. Through the Advanced Query interface, users may adjust the 
clustering parameters and build structure and model sets for custom analysis of their own data or 
to seamlessly access pre-analysis of over 975,000 missense mutations in 6,811 primary cancer 
studies catalogued by COSMIC. Owing to the amount of data already available via the 
mutation3D web interface and the continual accumulation of cancer sequencing and protein 
structural data, mutation3D is likely to produce future insights based on structural localization of 
mutations in the human proteome. 
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Figure Legends 
 
Figure 1. Missense mutations in both Mendelian disorders and cancer form clusters in tertiary 
protein structures. Linear protein models are given below each structure to illustrate the 
importance of studying 3D crystal structures. (a) Protein substitutions arising from mutations 
known to cause aromatase deficiency (in red) are shown overlaid upon an experimentally 
determined crystal structure of aromatase. Protein substitutions arising from common missense 
SNPs with MAF ≥ 1% (in blue) are shown to aggregate within regions of the protein structure 
that are distinct and spatially separated from those harboring the pathogenic substitutions, 
suggesting a strong relationship between the position of a substitution in the protein and its 
functional consequence(s). (b) Mutations causing amino acid substitutions in codons 12, 13 and 
61 account for over 99% of the mutations in GTPase KRas reported by COSMIC. The three most 
common amino acid substitutions at these positions (shown in red) form a tight cluster in a 
crystal structure of GTPase KRas, whereas a substitution (E49K) only observed once in 
COSMIC (shown in blue), is likely to be a passenger mutation and falls outside the 3D mutation 
cluster even though it appears to be in close proximity in the linear model.  
 
Figure 2. An overview of the mutation3D clustering and web accession procedures. (a) Sources 
of 3D protein structures and models and missense mutations in cancer. Pre-computation of 
clusters of amino acid substitutions for large data sets occurs with each COSMIC update. (b) 
There are three options for users to determine clustering: by inputting their own data as 
substitutions in single proteins (or nucleotide mutations in genes), by uploading a file of 
mutations, or by analyzing missense mutations from one of the 6,811 publications curated by 
26 
 
COSMIC. (c) The mutation3D web interface shows clusters on both linear models and 
interactive 3D models. Users may select among available models and structures. Individual 
queries will lead directly to this page, while batch queries will first lead to a table of proteins and 
clusters (shown below). 
 
Figure 3. (a-b) Known inherited disease-associated missense mutations from HGMD and 
missense SNPs from ESP 6500 with MAF ≥ 1% were clustered using mutation3D, with the 
percentage of variants within proteins containing clusters reported. (a) The combined set of 
resulting amino acid substitutions was plotted onto 3D protein models derived from the PDB 
alone, ModBase alone, and a combination of the two. (b) Fractions of clustered mutations were 
recalculated only for those mutations that reside within protein regions for which a 3D structure 
or model exists. (c-e) mutation3D was run on 285 WGS somatic tissue screens in COSMIC. (c) 
A higher fraction of protein candidates identified are known cancer genes at smaller values of 
cluster size (maximum cluster diameter). (d) A higher fraction of protein candidates identified 
are known cancer genes at smaller clustering P-values. (e) Mutations in tighter clusters are 
predicted by PolyPhen-2 to be more damaging than those in sparser clusters and in all WGS 
studies. (f) Mutations in tighter clusters are more likely to be observed at high frequency across 
COSMIC WGS studies. For all panels, * indicates P < 0.01. 
 
Figure 4. (a) The top 20 genes implicated in WGS studies by mutation3D ranked by the number 
of publications in which clusters were observed for each. (b) The most significant cluster for 
each of the 20 implicated genes are shown in 3D. 
